Share This Page
Suppliers and packagers for sandimmune
✉ Email this page to a colleague
sandimmune
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Novartis | SANDIMMUNE | cyclosporine | CAPSULE;ORAL | 050625 | NDA | Novartis Pharmaceuticals Corporation | 0078-0240-15 | 30 BLISTER PACK in 1 PACKAGE (0078-0240-15) / 1 CAPSULE, LIQUID FILLED in 1 BLISTER PACK (0078-0240-61) | 1990-03-02 |
| Novartis | SANDIMMUNE | cyclosporine | CAPSULE;ORAL | 050625 | NDA | Novartis Pharmaceuticals Corporation | 0078-0241-15 | 30 BLISTER PACK in 1 PACKAGE (0078-0241-15) / 1 CAPSULE, LIQUID FILLED in 1 BLISTER PACK (0078-0241-61) | 1990-03-02 |
| Novartis | SANDIMMUNE | cyclosporine | INJECTABLE;INJECTION | 050573 | NDA | Novartis Pharmaceuticals Corporation | 0078-0109-01 | 10 AMPULE in 1 BOX (0078-0109-01) / 5 mL in 1 AMPULE (0078-0109-61) | 1983-11-14 |
| Novartis | SANDIMMUNE | cyclosporine | SOLUTION;ORAL | 050574 | NDA | Novartis Pharmaceuticals Corporation | 0078-0110-22 | 50 mL in 1 BOTTLE (0078-0110-22) | 1983-11-14 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: SANDIMMUNE (Cyclosporine)
Introduction
Sandimmune, known generically as cyclosporine, is a crucial immunosuppressant used primarily to prevent organ rejection post-transplantation. Since its discovery, the drug has become a cornerstone in transplant medicine and autoimmune disease management. Given its high demand and complex manufacturing process, multiple suppliers worldwide have entered the market, providing raw materials, active pharmaceutical ingredients (APIs), and finished formulations. This comprehensive overview explores the key suppliers, their roles, and industry dynamics surrounding Sandimmune.
Overview of Sandimmune and Cyclosporine
Cyclosporine, first isolated in the 1970s from Tolypocladium inflatum, revolutionized transplant immunosuppression. Its formulation as Sandimmune by Novartis (now marketed by various generic producers) involves complex synthesis and purification processes to ensure purity, potency, and bioavailability. The initial patent for Sandimmune expired in the early 2000s, leading to a surge in generic production and an expanding supplier base.
Key Suppliers of Cyclosporine's Active Pharmaceutical Ingredient (API)
1. Bristol-Myers Squibb (BMS)**
While Bristol-Myers Squibb originally developed cyclosporine, the company now primarily markets the proprietary drug as Neoral and Sandimmune. Nonetheless, BMS also maintains controlled manufacturing of API and collaborates with external suppliers. Its legacy role positions it as both a primary supplier and a regulatory benchmark for quality standards.
2. Novartis**
As the original patent holder of Sandimmune, Novartis continues to oversee manufacturing processes, especially for branded formulations. The company maintains control over key stages of API synthesis and distribution, often sourcing raw materials from specialized suppliers to uphold product stability and efficacy. Novartis partners with manufacturing entities across multiple regions to meet global demand.
3. Sandoz (a Novartis division)**
Within Novartis' generics portfolio, Sandoz produces generic formulations of cyclosporine, often sourcing APIs from external manufacturers but adhering to strict quality standards aligned with regulatory agencies like the FDA and EMA.
4. Generics Manufacturers**
Post-patent expiration, numerous generic pharmaceutical companies became key players in the supply chain:
- Mylan (now part of Viatris): A significant supplier offering cyclosporine APIs and finished dosage forms globally.
- Teva Pharmaceuticals: One of the world's largest generics producers, Teva supplies cyclosporine formulations from APIs often sourced from third-party manufacturers.
- Aurobindo Pharma: An Indian-based manufacturer providing API and finished product, with a focus on cost-effective production.
- Cipla: Another major Indian GMP-compliant API producer, sensitive to regulatory standards and supply stability.
Major API Manufacturers
The production of cyclosporine APIs involves complex fermentation and synthesis, making specialized chemists and microbiologists vital:
- Mitsubishi Tanabe Pharma (Japan): Historically involved in biological fermentation processes for cyclosporine, Mitsubishi produces high-purity APIs with consistent batch-to-batch quality.
- Jubilant Life Sciences (India): A key player in API manufacturing, offering cyclosporine APIs compliant with international regulatory standards.
- Shin-Etsu Chemical Company: Engaged in manufacturing intermediates and APIs for immunosuppressant drugs, including cyclosporine.
Other notable suppliers include Granules India, HIKAL Ltd., and Zhejiang Hisun Pharmaceutical—all specializing in GMP-compliant API synthesis for global markets.
Supply Chain Dynamics and Market Trends
Globalization of API Production
The supply chain for cyclosporine APIs is highly internationalized. Indian companies, in particular, have emerged as cost-effective suppliers, benefiting from India's GMP standards and export-oriented manufacturing footprint. Chinese API producers also contribute significantly, with rapid scale-up capabilities and competitive pricing.
Regulatory Influence
Strict regulatory oversight from agencies like the FDA, EMA, and PMDA influences supplier selection. Suppliers with WHO-GMP, USFDA, and EMA certification are preferred by branded and generic manufacturers to ensure compliance and mitigate supply risks.
Supply Chain Challenges
Issues such as geopolitical tensions, regulatory modifications, and raw material shortages impact the stability of cyclosporine supplies. The COVID-19 pandemic further disrupted global manufacturing, emphasizing the need for diversified sourcing strategies.
Key Players and Their Strategic Focus
| Supplier | Role | Region | Strengths |
|---|---|---|---|
| Mitsubishi Tanabe Pharma | High-purity API production | Japan | Pharmaceutical R&D, fermentation expertise |
| Jubilant Life Sciences | Cost-effective API manufacture | India | GMP compliance, large-scale capacities |
| Shin-Etsu Chemical | Intermediate and API manufacturing | Japan | Process innovation |
| Cipla | API production, finished formulations | India | Extensive global distribution channels |
| Zhejiang Hisun Pharmaceutical | API manufacturing | China | Competitive pricing, GMP standards |
| Viatris (Mylan legacy) | Generics and API sourcing | Global | Market reach, regulatory expertise |
Quality and Regulatory Considerations
The technological complexity of cyclosporine manufacturing necessitates adherence to stringent quality controls. Suppliers must demonstrate compliance with Good Manufacturing Practice (GMP), stability testing, and batch consistency. Regulatory agencies frequently audit key manufacturing sites, and suppliers with established certifications are favored.
The recent emphasis on supply chain transparency, traceability, and pharmacovigilance underscores the importance of supplier due diligence, especially given past issues with counterfeit or substandard APIs.
Implications for Stakeholders
- Pharmaceutical companies should diversify their API sourcing to mitigate risks of shortages.
- Regulators should maintain rigorous certification and reporting standards for API manufacturers.
- Investors should monitor developments among leading API suppliers, especially Indian and Chinese manufacturers gaining market share.
Key Takeaways
- The manufacturing and supply of cyclosporine (Sandimmune) involve a network of global API producers, predominantly in Japan, India, and China.
- Post-patent expiration led to increased competition, driving down costs and expanding supply options.
- Regulatory compliance remains paramount; suppliers with established GMP certifications are preferred to ensure supply chain integrity.
- Market dynamics are influenced by geopolitical factors, supply chain disruptions, and evolving industry standards.
- Manufacturers and healthcare providers should prioritize diversification and quality assurance to ensure uninterrupted access to Sandimmune.
FAQs
1. Who are the leading suppliers of cyclosporine API?
Major API suppliers include Mitsubishi Tanabe Pharma (Japan), Jubilant Life Sciences (India), Shin-Etsu Chemical (Japan), Cipla (India), and Zhejiang Hisun Pharmaceutical (China).
2. How has the expiration of patent protections affected the supplier landscape?
Patent expiry facilitated entry by generic manufacturers, increasing competition, reducing prices, and broadening the supplier base.
3. What are the primary quality considerations for suppliers of Sandimmune?
Suppliers must maintain GMP compliance, demonstrate batch consistency, possess relevant certifications (e.g., FDA, EMA), and adhere to strict validation protocols.
4. How are supply chain risks managed in cyclosporine manufacturing?
Diversification of sourcing, rigorous regulatory oversight, contingency planning, and maintaining multiple supplier relationships mitigate risks.
5. What role do regional geopolitical issues play in the supply chain?
Trade tensions, export restrictions, and raw material access can disrupt supply, emphasizing the need for strategic sourcing across multiple regions.
References
[1] U.S. Food and Drug Administration. “Cyclosporine API and drug approval data.” (2022).
[2] Novartis AG. “Sandimmune: Product information and manufacturing insights.” (2021).
[3] MarketLine. “Global Immunosuppressant Market Report.” (2022).
[4] Indian Pharmaceutical Association. “API manufacturing landscape.” (2021).
[5] European Medicines Agency. “GMP certifications for API producers.” (2022).
More… ↓
